IHC - GCDFP15

The IHC – GCDFP-15 (Gross Cystic Disease Fluid Protein-15) test is an advanced immunohistochemistry (IHC) diagnostic test used to identify the presence of GCDFP-15 protein in tissue samples. This marker is commonly associated with breast tissue and is highly valuable in diagnosing breast-origin tumors, especially metastatic breast carcinoma.

GCDFP-15 is a glycoprotein normally produced by certain breast epithelial cells. When detected in abnormal tissue samples, it helps pathologists confirm whether the tumor originated from breast tissue. This test is especially useful when cancer has spread to distant organs and the primary site is unclear.

The GCDFP-15 test is often performed as part of a broader immunohistochemistry panel along with markers such as ER, PR, HER2, and Mammoglobin to improve diagnostic accuracy and establish tumor origin.

Benefits of the Test

The GCDFP-15 IHC test offers several important diagnostic benefits:

• Helps confirm breast tissue origin in tumors
• Assists in diagnosing metastatic breast carcinoma
• Differentiates breast cancer from tumors of other origins
• Supports accurate tumor classification
• Helps guide treatment planning and prognosis assessment

This marker is especially valuable in cases where tumor origin is uncertain after routine histopathology evaluation.

Why Doctors Recommend This Test

Doctors recommend the GCDFP-15 IHC test when there is suspicion of metastatic breast cancer or when abnormal tissue is found in distant organs such as lymph nodes, liver, lung, skin, or bone. It helps determine whether these tumors are secondary deposits from breast carcinoma.

This test is frequently used in patients with:

• History of breast cancer
• Suspected recurrent breast carcinoma
• Metastatic tumors of unknown primary origin
• Cases requiring detailed breast cancer profiling

The results help oncologists choose appropriate therapies such as hormone therapy, chemotherapy, or targeted treatment.

Preparation Before Test

No special preparation is required from the patient. The test is performed on biopsy or surgically removed tissue samples already collected during diagnostic procedures.

Normal Reporting Time

The normal turnaround time for the GCDFP-15 IHC test is 2 to 4 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients with suspected metastatic breast carcinoma
• Individuals with tumors of unknown primary origin
• Patients with previous breast cancer history
• Cases needing breast tumor confirmation
• Oncology diagnostic evaluations requiring breast markers

The IHC GCDFP-15 test is an essential pathology tool for confirming breast-origin tumors. Its accuracy helps doctors diagnose metastatic breast cancer correctly and supports personalized treatment planning, leading to better clinical outcomes.